@FiercePharma: Oculus leaps into animal health with 6 new skin and eye products. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. Article | Follow @EricPFierce
@CarlyHFierce: ICYMI: Bayer counts on consumer health, pharma growth to power 2015. Story | Follow @CarlyHFierce
> Mylan ($MYL) wrapped up its $5.3 billion buyout of a portfolio of Abbott Laboratories' ($ABT) specialty and branded generics, focused on developed markets outside the U.S.; the deal gives Mylan a new, tax-friendly location in the Netherlands and more heft in international markets. Release
> Novo Nordisk ($NVO) hiked the price range for its planned IPO for the technology services subsidiary NNIT, to 120 to 130 Danish crowns ($18 to $19) from 100 to 120 crowns. Report
> Actavis ($ACT) reportedly has started marketing bonds in a 9-part offering worth as much as $22 billion; the debt sale will finance its buyout of Botox-maker Allergan ($AGN). Report
> The FDA rejected Pacira Pharmaceuticals' application to expand the use of Exparel, a treatment for surgery-related pain, to other nerve-numbing uses. Report
> An Actavis intrauterine device that releases the hormone levonorgestrel, Liletta, won FDA approval to prevent pregnancy for up to three years. Report
> The FDA is requiring additional warnings on multidose diabetes pens, prohibiting patients from sharing the devices, because of the risk of infection. Report
Medical Device News
@FierceMedDev: Startup Akili partners with nonprofit Autism Speaks to test video game. News | Follow @FierceMedDev
@VarunSaxena2: ICYMI: More lawsuits planned as infected endoscope safety scare grows. More | Follow @VarunSaxena2
> J&J confirms $1.9B sale of Cordis unit to Cardinal Health, ending months of speculation. Story
> FDA approves Actavis intrauterine device to prevent pregnancy. Article
> Startup Akili partners with nonprofit Autism Speaks to test video game. More
Biotech News
@FierceBiotech: From FierceDrugDelivery: UPDATED: @US_FDA agrees to review $ENDP's inside-the-cheek pain drug. More | Follow @FierceBiotech
@JohnCFierce: Interested in ADCs and VC cash? Mersana grabs a $35M round, posts ex-Millennium chief Protopapas at helm. Article | Follow @JohnCFierce
@DamianFierce: The fake Immunovaccine release reads like a parody of bio stock pumping. Image | Follow @DamianFierce
> As PhII data looms, Chugai inks a $205M stem cell deal with Athersys. Article
> Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease. Report
> China biotech makes FDA 'breakthrough' for HIV drug. Item
Biotech IT News
> RainDance files for $60M IPO. Item
> Novo Nordisk set to rake in up to $335M from IT unit IPO. Report
> Eccrine bags seed funding for Air Force-developed sweat sensor. News
> Analyst casts doubt on Big Data potential of Covance-LabCorp merger. Story
> H3 hooks up with Foundation Medicine for data-driven oncology R&D. Article
CRO News
> Charles River embraces discovery in management shake-up. News
> Catalent beefs up its European network for clinical supplies. Story
> Enteris gets into contract manufacturing with new plant. Item
> INC Research soars in its first post-IPO quarter. Report
> Icon rides a revenue leap into another growth year. Article
Animal Health News
> Bayer to close animal health plant in St. Joseph, MO; sell-off some product lines. More
> Aratana regains dog lymphoma drug from Lilly for 'great price,' say analysts. Story
> Purina faces lawsuit over dogs allegedly sickened by Beneful. Item
> Oculus leaps into animal health with 6 new skin and eye products. Article
> Parnell records strong sales growth, stays focused on arthritis approval. Report
And Finally... India has tightened up its healthcare budget for 2015-2016, a move that disappointed advocates of improved access to care. Report